TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15834740

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and silver-sulfadiazine (CHSS) coated catheters
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control catheters (uncoated)
Number of subjects: 184
Study: 12616982

Group type: EXPERIMENTAL
Intervention: Oral 17 beta-oestradiol daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 10518081

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (4 IU/m(2)/d, 6 IU/m(2)/d, 8 IU/m(2)/d)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 68
Study: 7793204

Group type: EXPERIMENTAL
Intervention: Flumazenil 10 micrograms.kg‐1 (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (Group A)
Number of subjects: 40
Study: 1958603

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine plus 1 mg butorphanol plus 1:300,000 epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1.5% lidocaine plus 1:300,000 epinephrine
Number of subjects: 50
Study: 7216122

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 315

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 315
Study: 30259799

Group type: EXPERIMENTAL
Intervention: Employed individuals
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Unemployed individuals
Number of subjects: 1000
Study: 30450593

Group type: EXPERIMENTAL
Intervention: Sinus Crestal Approach (SCA) drill kit technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional osteotome technique
Number of subjects: 12
Study: 27352623

Group type: EXPERIMENTAL
Intervention: NIAT-rituximab (375 mg/m2 intravenous rituximab on days 1 and 8)
Number of subjects: 75

Group type: COMPARATOR
Intervention: NIAT alone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: NIAT-rituximab
Number of subjects: 75

Group type: COMPARATOR
Intervention: NIAT
Number of subjects: 75
Study: 25599299

Group type: EXPERIMENTAL
Intervention: Emla with suggestions of analgesia
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Emla with suggestions of hyperalgesia
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo with suggestions of analgesia
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Placebo with suggestions of hyperalgesia
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Emla with no specific information
Number of subjects: 142

Group type: COMPARATOR
Intervention: No treatment with pain induction
Number of subjects: 142
Study: 23700938

Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions (CAPDP-2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard PD solutions (CAPDP-1)
Number of subjects: 42
Study: 21881371

Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine physical therapy after operation
Number of subjects: 60
Study: 18782649

Group type: EXPERIMENTAL
Intervention: Caffeine (3mg/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16761153

Group type: EXPERIMENTAL
Intervention: Trilogy Calcicoat (HA/TCP coated)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Porous coated Trilogy
Number of subjects: 100
Study: 15207665

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 80
Study: 11269453

Group type: EXPERIMENTAL
Intervention: Single aortic cross-clamping technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Partial occluding aortic clamp
Number of subjects: 50
Study: 10933420

Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Food Records
Number of subjects: 13

Group type: COMPARATOR
Intervention: 24-hour Diet Recalls
Number of subjects: 13

Group type: COMPARATOR
Intervention: Food Records and 24-hour Diet Recalls
Number of subjects: 13

Group type: COMPARATOR
Intervention: Analysis of Variance
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Recalls
Number of subjects: 13
Study: 7742263

Group type: EXPERIMENTAL
Intervention: Felodipine ER (FER) 5 mg once daily, increased to 10 mg if necessary
Number of subjects: 98

Group type: COMPARATOR
Intervention: Diltiazem SR (DSR) 90 mg twice daily, increased to 120 mg if necessary
Number of subjects: 98
Study: 2264429

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sclerotherapy alone (Control)
Number of subjects: 41
Study: 35197

Group type: EXPERIMENTAL
Intervention: Clobazam (dosage ranged from 5 mg daily to 120 mg daily, usual daily dosage in out-patient therapy 20-30 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clobazam (dosage ranged from 5 mg daily to 120 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clobazam
Number of subjects: 45
Study: 31879231

Group type: EXPERIMENTAL
Intervention: Endovenous treatment with lysis and stenting
Number of subjects: 11
Study: 31664975

Group type: EXPERIMENTAL
Intervention: Standardised Packaging (without health warnings)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Standardised Packaging with Health Warnings
Number of subjects: 625

Group type: COMPARATOR
Intervention: Branded Packaging
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Standardised Packaging (both types)
Number of subjects: 625
Study: 28608121

Group type: EXPERIMENTAL
Intervention: Neoadjuvant S-1 with concurrent hypofractionated radiotherapy (30 Gy in 10 fractions, S-1 at 60 mg/m2, 5 days/week for 2 weeks)
Number of subjects: 57
Study: 25645170

Group type: EXPERIMENTAL
Intervention: Adjunctive intervention consisting of two sessions of psychoeducation and skills training in reducing accommodation.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard individual exposure and ritual prevention (ERP) for OCD.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Change in family accommodation from baseline.
Number of subjects: 18
Study: 23921928

Group type: EXPERIMENTAL
Intervention: Inverted J‐shaped incision with bony tie‐down suture
Number of subjects: 31

Group type: COMPARATOR
Intervention: Minimally invasive incision without tie‐down suture
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative computed tomography (in 10 patients)
Number of subjects: 31
Study: 21241514

Group type: EXPERIMENTAL
Intervention: DECISION+ program (three 3-hour workshops over a four- to six-month period)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Control group (delayed exposure to the DECISION+ program)
Number of subjects: 544
Study: 19259861

Group type: EXPERIMENTAL
Intervention: Exam-room posters designed by the ACS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posters plus patient reminder calls from an ACS volunteer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16680107

Group type: EXPERIMENTAL
Intervention: Bimanual microincision phacoemulsification using WhiteStar technology
Number of subjects: 33
Study: 15486569

Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Topiramate 256 mg/day
Number of subjects: 1289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Topiramate (all doses)
Number of subjects: 1289
Study: 11507297

Group type: EXPERIMENTAL
Intervention: Protocol 2 (our protocol): 100 microCi (10 microl) Tc‐99m pertechnetate instilled in the outer canthus of the eye using a micropipette with the patient in the supine position under the gamma camera. Dynamic images taken for only 5 minutes.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Protocol 1 (the current conventional protocol): 50 microl Tc‐99m pertechnetate containing 50 to 100 microCi radioactivity instilled in the inferior fornix or outer canthus of the eye. Dynamic and static images obtained for approximately 15 to 20 minutes.
Number of subjects: 77
Study: 9570195

Group type: EXPERIMENTAL
Intervention: HTLf (helper T cells)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CTLf (cytotoxic T cells)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Third-party control
Number of subjects: 10
Study: 7809641

Group type: EXPERIMENTAL
Intervention: Wrist immobilized in neutral flexion‐extension (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wrist dorsiflexed 20 degrees (Group 2)
Number of subjects: 50
Study: 3055950

Group type: EXPERIMENTAL
Intervention: Virucidal nasal tissues (impregnated with malic and citric acids and sodium lauryl sulfate)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo tissues (saccharin in trial I; mixture including succinic acid in trial II)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Virucidal nasal tissues
Number of subjects: 284
Study: 1093658

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sulfamethoxazole (SMX) alone
Number of subjects: 90
Study: 31964579

Group type: COMPARATOR
Intervention: LITE (educational intervention with 2 phone calls)
Number of subjects: 614

Group type: COMPARATOR
Intervention: PLUS (educational intervention with biweekly calls until content competency)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 614
Study: 31280079

Group type: EXPERIMENTAL
Intervention: PTSD symptom clusters (Negative Alterations in Cognition and Mood and Alterations in Arousal and Reactivity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General distress factor
Number of subjects: 0
Study: 27465573

Group type: EXPERIMENTAL
Intervention: 27‐gauge (G) pars plana vitrectomy (PPV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 25‐G pars plana vitrectomy (PPV)
Number of subjects: 30
Study: 23598540

Group type: EXPERIMENTAL
Intervention: High FABP4 concentrations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intermediate FABP4 concentrations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low FABP4 concentrations
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intermediate and high FABP4 concentrations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: FABP4
Number of subjects: 108
Study: 21478734

Group type: EXPERIMENTAL
Intervention: NPPV (noninvasive positive pressure ventilation)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: NPPV + RM (noninvasive positive pressure ventilation followed by recruitment maneuver)
Number of subjects: 66

Group type: COMPARATOR
Intervention: CON (conventional preoxygenation with spontaneous breathing of 100% O₂)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: NPPV + RM
Number of subjects: 66
Study: 19451404

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg single dose
Number of subjects: 44
Study: 16934728

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 43

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 43
Study: 15252193

Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg at bedtime for one week followed by 2 mg at bedtime for one week
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10904465

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (extended out-of-hospital prophylaxis for 35 days)
Number of subjects: 569

Group type: COMPARATOR
Intervention: In-hospital warfarin/out-of-hospital placebo
Number of subjects: 569
Study: 9060195

Group type: EXPERIMENTAL
Intervention: 24-hour transdermal nicotine patch
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sustained abstainers
Number of subjects: 100
Study: 8359959

Group type: EXPERIMENTAL
Intervention: Self-reported snoring
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: RDI >= 5
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Self-reported snores
Number of subjects: 1504
Study: 2943049

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28858412

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 27070089

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 10074

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 10074

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 10074
Study: 25486675

Group type: COMPARATOR
Intervention: Computer tailoring
Number of subjects: 393

Group type: COMPARATOR
Intervention: Health counseling
Number of subjects: 393
Study: 22762942

Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical prophylaxis
Number of subjects: 0
Study: 20697307

Group type: EXPERIMENTAL
Intervention: Tailored newsletters
Number of subjects: 225

Group type: COMPARATOR
Intervention: Generic newsletters
Number of subjects: 225
Study: 18683717

Group type: EXPERIMENTAL
Intervention: Preoperative computer-aided design (CAD) system
Number of subjects: 182

Group type: COMPARATOR
Intervention: Traditional preoperative templating
Number of subjects: 182
Study: 15735186

Group type: EXPERIMENTAL
Intervention: Instant total contact cast (iTCC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Removable cast walker (RCW)
Number of subjects: 50
Study: 12928815

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), 5 times a week for 6 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard decubitus care (control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Norton scores
Number of subjects: 86
Study: 10510109

Group type: EXPERIMENTAL
Intervention: Propiverine (15 mg three times daily)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg twice daily)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Propiverine
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Overall assessment of efficacy
Number of subjects: 366
Study: 8683844

Group type: EXPERIMENTAL
Intervention: GnRH‐agonist therapy after drainage of endometrioma for 6 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: GnRH‐agonist therapy alone for 6 months
Number of subjects: 26
Study: 1984619

Group type: EXPERIMENTAL
Intervention: Comprehensive home and ambulatory program for pediatric asthma management including 3-month clinic visits, education, and home visits by a specially trained research nurse.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Comprehensive home and ambulatory program for pediatric asthma management.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Regular care from a family physician or pediatrician (Control).
Number of subjects: 95
Study: 6524855

Group type: EXPERIMENTAL
Intervention: Flexible choledochoscopy
Number of subjects: 197

Group type: COMPARATOR
Intervention: Postexploratory T‐tube cholangiography
Number of subjects: 197

Group type: COMPARATOR
Intervention: No postexploratory control
Number of subjects: 197
Study: 30947755

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29534070

Group type: EXPERIMENTAL
Intervention: Health education program on foot self-care behaviour
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 76
Study: 27265353

Group type: EXPERIMENTAL
Intervention: Daily oral co-trimoxazole prophylaxis (120 mg/day for <6 months, 240 mg/day for 6 months to 5 years)
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1778

Group type: EXPERIMENTAL
Intervention: Daily oral co-trimoxazole prophylaxis
Number of subjects: 1778
Study: 24251726

Group type: EXPERIMENTAL
Intervention: Remote past left ventricular ejection fraction (RP‐LVEF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: RP‐LVEF ≥ 43.5%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intrinsic QRS width, septal‐posterior wall motion delay, or tissue Doppler‐derived dyssynchrony indexes
Number of subjects: 25
Study: 22285724

Group type: EXPERIMENTAL
Intervention: Atomoxetine (mean final dose = 1.38 mg/kg)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Atomoxetine (mean final dose = 1.21 mg/kg)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 271
Study: 19652932

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy (7.0 Gy) and indomethacin for 15 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Indomethacin alone for 15 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Historical control group receiving indomethacin alone
Number of subjects: 96
Study: 16998214

Group type: EXPERIMENTAL
Intervention: Statin treatment (mainly atorvastatin) in Group A
Number of subjects: 712

Group type: COMPARATOR
Intervention: No statin treatment in Group B
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Statin treatment in Group C (without MetS)
Number of subjects: 712

Group type: COMPARATOR
Intervention: No statin treatment in Group D (without MetS)
Number of subjects: 712
Study: 15237767

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 mg/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 12395977

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 9804507

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Trifluoperazine (TFP)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Verapamil (VER)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mannitol (MAN)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 125
Study: 7700960

Group type: EXPERIMENTAL
Intervention: De-nicotinized cigarette (de-nic)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 7

Group type: COMPARATOR
Intervention: Regular cigarette and de-nic cigarette
Number of subjects: 7
Study: 2717287

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (pacifier for 30 minutes with each feeding, 12 times per day until weight of 1,500 g, then 8 times per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no pacifier)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (in subgroup of boys)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (in subgroup of boys)
Number of subjects: 18
Study: 1098832

Group type: EXPERIMENTAL
Intervention: 1 mg of folic acid daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 mg of folic acid daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0 mg of folic acid after dialysis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 mg of folic acid after dialysis
Number of subjects: 9
Study: 31870188

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30636184

Group type: EXPERIMENTAL
Intervention: Wholemeal rye bread (WMR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Refined wheat bread (WB)
Number of subjects: 9
Study: 28534200

Group type: EXPERIMENTAL
Intervention: Unloading using the Hephaistos orthosis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control leg (no unloading)
Number of subjects: 12
Study: 26906426

Group type: EXPERIMENTAL
Intervention: Active familiarization (listeners heard audio recordings of words while viewing the written material of words)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Passive familiarization (listeners heard audio recordings of words)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition (listeners had no exposure to the audio signal prior to identification tasks)
Number of subjects: 120
Study: 23510124

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 90 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo once daily for 90 days
Number of subjects: 86
Study: 21574975

Group type: EXPERIMENTAL
Intervention: wIRA + VIS
Number of subjects: 51

Group type: COMPARATOR
Intervention: VIS alone
Number of subjects: 51
Study: 17934999

Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT) part A
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT) part B
Number of subjects: 643
Study: 16791015

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 352
Study: 15587537

Group type: EXPERIMENTAL
Intervention: Dorsal block and ring block in combination with concentrated oral sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concentrated oral sucrose alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 0
Study: 11717622

Group type: EXPERIMENTAL
Intervention: Oral beta(2)-adrenergic receptor agonists (beta(2)-AG)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cessation of oral beta(2)-adrenergic receptor agonists (beta(2)-AG) for 2 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion with heart rate adjusted to 90 beats/min
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal volunteers without heart or pulmonary diseases (control group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Patients without beta(2)-adrenergic receptor agonists (group B)
Number of subjects: 74
Study: 9137794

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC: 3000 mg/sqm every 12 hours as one-hour infusion for six days)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard-dose cytarabine (SDAC: 100 mg/sqm 24 hours infusion over seven days)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard-dose cytarabine (SDAC)
Number of subjects: 137
Study: 7944756

Group type: EXPERIMENTAL
Intervention: Single layer of continuous absorbable monofilament (Maxon)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Single layer of interrupted Polyglactin sutures (Vicryl)
Number of subjects: 42